Medical : Gynecology & Obstetrics

60 high-yield cases in Obstetrics and Gynecology help you to excel in the clerkship and improve your shelf-exam score. You need exposure to high-yield cases to excel on the Obstetrics and Gynecology clerkship and the shelf-exam. Case Files: Obstetrics and Gynecology presents 60 real-life cases that illustrate essential concepts in Obstetrics and Gynecology. Each case includes a complete discussion, clinical pearls, references, definitions of key terms, and USMLE-style review questions. With this system, you'll learn in the context of real patients, rather than merely memorize facts.: 60 clinical cases, each with USMLE-style questions; Clinical pearls highlight key concepts; Primer on how to approach clinical problems and think like a doctor; Proven learning system improves your shelf-exam scores more...

Price: $32.95

All four editors of this title are extremely prominent in the field of PCOS. Although they are all U.S.-based, they are internationally renowned. The book includes the latest diagnostic criteria for PCOS, and comprises the most up to date information about the genetic features and pathogenesis of PCOS. The diagnostic criteria for PCOS took shape in 1990 following an NIH conference co-organized by Dr. Dunaif, resulting in her classic volume, Polycystic Ovary Syndrome (1992). That title recommended diagnostic criteria of hyperandrogenism and chronic anovulation with the exclusion of specific disorder of the ovary, adrenal, and pituitary. These criteria dominated the field but were revised in 2003 by a working group of international experts at a conference in Rotterdam. Since then, it has become increasingly clear over the past several years that PCOS is a complex genetic disease resulting from the interaction of susceptibility genes and environmental factors. This volume critically reviews the methodological approaches and the evidence for various PCOS susceptibility genes. Additional familial phenotypes of PCOS and their potential genetic basis are also discussed. In all, this title is comprehensive and replete with the latest in expert recommendations on PCOS. This expert opinion remains critical to guiding practice in PCOS because sufficient data for evidence-based guidelines remains scarce. more...

Price: $149.00

This edition has been thoroughly updated and revised with new photographs and illustrations, and addresses some of the current most controversial issues such as the role of the midwife and GP, the need for decentralization of management and home births and screening. more...

Price: $31.95

Preterm birth is a major challenge in perinatal health care. Most perinatal deaths occur in preterm infants, and preterm birth is an important risk factor for neurological damage, including cerebral palsy. This ABC covers all the latest information on this complex and multidisciplinary area from obstetric issues to immediate care of preterm infants, respiratory complications, and how to provide support to the parents and relatives of the preterm infant. With its clear explanation and many illustrations, general practitioners, medical students, paediatricians starting their postgraduate training, nurses, and midwives will find ABC of Preterm Birth an excellent reference. more...

Price: $35.95

Over the last 5 years significant advances have been made in our understanding of the biology of breast cancer. As a result of linking observations made in the laboratory to new treatment strategies, the outcome of breast cancer patients with both early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer. The initial discussion will focus on the evolving understanding of the genetics of breast cancer. (Olapade or Pasche) In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified will be discussed. In addition, strategies for surveillance of high-risk populations and prevention strategies under evaluation are highlighted. The underlying molecular pathways that control malignant cell growth are being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some of the agents farthest along in clinical development. Though novel therapeutic agents or "targeted therapy" hold significant promise, standard treatment modalities including chemotherapy, endocrine therapy, surgery and radiation therapy will remain important for management of breast cancer patients. The decision to offer patients with early stage breast cancer systemic adjuvant therapy has been made based largely on clinical parameters including tumor size and nodal status. Clinicians have longrecognized that this method of evaluating risk of recurrence for an individual patient is imprecise. Much research over the last several years has focused on developing molecular profiles of individual tumors that correlate with long-term outcome. Dr. Paik will discuss the development of this more...

Price: $139.00